ScreenerHero
BXPBeximco Pharmaceuticals Limited
LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · beximcopharma.com
55.00GBP0.00%Mkt Cap: 314.70M $P/E: 4.58

Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and an…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap314.70M $
Enterprise Value—
Revenue (TTM)—
Gross Profit28.60B $
Net Income (TTM)8.90B $
Revenue/Share—
Last Price55.00 GBP
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees6.0K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)4.58
P/E (Forward)0.07
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)0.12
EPS (Forward)8.14
52W Range
54.3322% of range57.40
52W High57.40 GBP
52W Low54.33 GBP
Profitability
Gross Margin45.39%
Oper. Margin0.00%
EBITDA Margin24.31%
Profit Margin14.13%
ROE13.07%
ROA9.48%
Growth
Revenue Growth8.10%
Earnings Growth29.00%
Cash Flow & Leverage
Operating CF9.26B $
CapEx (TTM)3.89B $
FCF Margin—
FCF Yield1700.40%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.09
Current Ratio4.13
Quick Ratio1.40
Book Value/Sh111.35 GBP
Cash/Share—
Dividends
Fwd Div Rate0.0300 GBP
Trail. Div Rate0.0000 GBP
Div. Yield5.11%
5Y Avg Yield5.22%
Payout Ratio0.00%
Ex-Div DateJul 31, 2026
Pay Date—
Splits
Last Split110:100
Split DateNov 23, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.446.11M
Float—
Insiders0.00%
Institutions0.29%
Technical
SMA 5046.37 (+18.6%)
SMA 20019.30 (+185.0%)
Beta0.25
S&P 52W Chg18.16%
Avg Vol (30d)16.52K
Avg Vol (10d)32.85K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—